MEPOLIZUMAB

Brand name:

• Nucala®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

GLAXOSMITHKLINE AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Chronic rhinosinusitis with nasal polyps

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to PBS listing (–)

Comment:

--

Other PBAC consideration:

--

Submission received for:

November 2022 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 02/11/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/12/2022

Lodgement of required documentation:

14/12/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 20/12/2022

Status:

Finalised

Government processes:

Commenced on 24/01/2023

Medicine listed on the PBS:

01/04/2023 (see PBS schedule)